HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer

HER2 status in breast cancer is assessed to select patients eligible for targeted therapy with anti-HER2 therapies. According to the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP), the HER2 test positivity is defined by protein overexpression (score 3+) at im...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Konstantinos Venetis, Edoardo Crimini, Elham Sajjadi, Chiara Corti, Elena Guerini-Rocco, Giuseppe Viale, Giuseppe Curigliano, Carmen Criscitiello, Nicola Fusco
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2022-03-01
سلاسل:	Frontiers in Molecular Biosciences
الموضوعات:	breast cancer biomarkers HER2 low expression HER2 ultra low targeted therapy antibody-drug conjugate
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fmolb.2022.834651/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!